NCT01619111View on ClinicalTrials.gov

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

PHASE3CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions
HER2-negative Metastatic Breast CancerHER2-positive Circulating Tumor Cells
Interventions
DRUG

standard chemo- or endocrine therapy

"standard chemo- or endocrine therapy:~* Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~* Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)"

DRUG

standard chemo- or endocrine therapy + Lapatinib

"Lapatinib~\+ standard chemo- or endocrine therapy:~* Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~* Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)"

Trial Locations (1)

89075

University Hospital Ulm, Ulm

All Listed Sponsors
lead

Prof. Wolfgang Janni

OTHER

NCT01619111 - DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs | Biotech Hunter | Biotech Hunter